Tiefenbacher Group at CPHI Frankfurt 2025

After weeks of preparation, the countdown is finally over. Next week, our Tiefenbacher Group team will be at CPHI in Frankfurt. Before we unveil our new booth design, take a look back at some impressions from last year’s CPHI: engaging discussions, inspiring meetings, and many valuable connections with our global partners. From 28th of October […]
Tiefenbacher Group wishes you a happy new year!

As 2024 draws to a close, the Tiefenbacher Group wishes you a Happy New Year and likes to share some of the year’s highlights with you. This year we celebrated many achievements: several international launches of prescription medicines, the preparation for Bilastine’s over-the-counter entry in Germany, the renovation of our Hamburg offices, and the construction […]
Tiefenbacher Group CPHI Milan 2024

Tiefenbacher Group reflecting on incredible days at CPHI in Milan!We had the pleasure of engaging in many inspiring conversations over the course of the three days, reconnecting with familiar faces and forming exciting new connections. A highlight was our new booth where we introduced our current product portfolio and our innovations in raw materials, finished […]
OYSTA receives UX Design Award 2024

We are happy to announce that our beloved OYSTA project has been awarded with the prestigious UX Design Award.Thanks to the outstanding work of our partner Star, a global technology consultancy, which takes care of OYSTA Digital Service, the companion to our OYSTA Dosage Manager. In recognition of the exceptional design and innovation behind the […]
TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES

Innovation healthcare by combining established drug-based medicines with medical devices and digital healthAfter more than five years in operation, TIEFENBACHER GROUP transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES. The launch follows TIEFENBACHER GROUP´s strategy to offer better patient therapies by combining established drug-based medicines with medical devices and digital […]